Nova Ltd vs GeneDx Holdings Corp — how do they compare? Nova Ltd trades at $353 (market cap $11.28B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Nova Ltd is far larger — about 5.6× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 394,997). Which is the better fit depends on your goals — on Pluang, investors hold Nova Ltd for 4 Days and GeneDx Holdings Corp for 19 Days on average.
| NVMI | WGS | |
|---|---|---|
Market Cap | $11.28B | $2.02B |
Volume | 394,997 | 734,640 |
Sector | Technology | Health |
52-Week High | $605.65 | $167.51 |
52-Week Low | $275.78 | $34.51 |
Typical Hold Time | 4 Days | 19 Days |
Enterprise Value | $11.06B | $2.05B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $67.73, down 1.17% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations, and returned to adjusted profitability early. However, 2026 fundamentals show concerning trends with a net loss of $106 million and negative profit margins. Recent news highlights product innovations and leadership recognition, while technical analysis indicates the stock is trading near key support at $66.
The investment outlook presents a dichotomy between strong analyst conviction (90.9% buy ratings, $81 consensus target) and challenging fundamentals. While operational improvements and genomic testing growth offer potential upside, persistent losses and negative cash flow trends create significant execution risk. The stock's current position near support levels combined with oversold RSI readings suggests potential for near-term bounce, but sustainable gains require meaningful profitability improvements.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nova provides metrology solutions for semiconductor manufacturing. Its systems measure material and process characteristics to help chipmakers control production across advanced nodes and packaging.
Read more on NVMI →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →